

# Natalia L Laufer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5119911/publications.pdf>

Version: 2024-02-01

46  
papers

808  
citations

516561

16  
h-index

552653

26  
g-index

50  
all docs

50  
docs citations

50  
times ranked

1459  
citing authors

#	ARTICLE	IF	CITATIONS
1	MicroRNAs differentially present in the plasma of HIV elite controllers reduce HIV infection in vitro. <i>Scientific Reports</i> , 2014, 4, 5915.	1.6	82
2	Sputnik V vaccine elicits seroconversion and neutralizing capacity to SARS-CoV-2 after a single dose. <i>Cell Reports Medicine</i> , 2021, 2, 100359.	3.3	62
3	Acute retroviral syndrome and high baseline viral load are predictors of rapid HIV progression among untreated Argentinean seroconverters. <i>Journal of the International AIDS Society</i> , 2011, 14, 40-40.	1.2	55
4	Early Gag Immunodominance of the HIV-Specific T-Cell Response during Acute/Early Infection Is Associated with Higher CD8 <sup>+</sup> T-Cell Antiviral Activity and Correlates with Preservation of the CD4 <sup>+</sup> T-Cell Compartment. <i>Journal of Virology</i> , 2013, 87, 7445-7462.	1.5	53
5	Th17 and Th17/Treg ratio at early HIV infection associate with protective HIV-specific CD8 <sup>+</sup> T-cell responses and disease progression. <i>Scientific Reports</i> , 2015, 5, 11511.	1.6	47
6	Env-Specific IgA from Viremic HIV-Infected Subjects Compromises Antibody-Dependent Cellular Cytotoxicity. <i>Journal of Virology</i> , 2016, 90, 670-681.	1.5	39
7	A Possible Sterilizing Cure of HIV-1 Infection Without Stem Cell Transplantation. <i>Annals of Internal Medicine</i> , 2022, 175, 95-100.	2.0	36
8	Magnitude, Breadth, and Functional Profile of T-Cell Responses during Human Immunodeficiency Virus Primary Infection with B and BF Viral Variants. <i>Journal of Virology</i> , 2008, 82, 2853-2866.	1.5	34
9	Expansion of CD25-Negative Forkhead Box P3-Positive T Cells during HIV and Mycobacterium tuberculosis Infection. <i>Frontiers in Immunology</i> , 2017, 8, 528.	2.2	30
10	Early Skewed Distribution of Total and HIV-Specific CD8 <sup>+</sup> T-Cell Memory Phenotypes during Primary HIV Infection Is Related to Reduced Antiviral Activity and Faster Disease Progression. <i>PLoS ONE</i> , 2014, 9, e104235.	1.1	28
11	Impact of HIV-ART on the restoration of Th17 and Treg cells in blood and female genital mucosa. <i>Scientific Reports</i> , 2019, 9, 1978.	1.6	22
12	Extrahepatic manifestations of HCV: the role of direct acting antivirals. <i>Expert Review of Anti-Infective Therapy</i> , 2017, 15, 737-746.	2.0	21
13	PD-1 Expression in HIV-Specific CD8 <sup>+</sup> T cells Before Antiretroviral Therapy Is Associated With HIV Persistence. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 80, 1-6.	0.9	21
14	Hepatitis B precore/core promoter mutations in isolates from HBV-monoinfected and HBV+HIV coinfecting patients: A 3-yr prospective study. <i>Journal of Clinical Virology</i> , 2009, 46, 354-359.	1.6	20
15	Longitudinal Study after Sputnik V Vaccination Shows Durable SARS-CoV-2 Neutralizing Antibodies and Reduced Viral Variant Escape to Neutralization over Time. <i>MBio</i> , 2022, 13, e0344221.	1.8	19
16	Hepatitis B Virus, Hepatitis C Virus and HIV Coinfection Among People Living With HIV/AIDS in Buenos Aires, Argentina. <i>Sexually Transmitted Diseases</i> , 2010, 37, 342-343.	0.8	17
17	HCV genotype distribution among HIV co-infected individuals in Argentina: relationship with host and viral factors. <i>Acta Gastroenterologica Latinoamericana</i> , 2007, 37, 76-83.	0.0	16
18	HIV-1 Tropism Dynamics and Phylogenetic Analysis from Longitudinal Ultra-Deep Sequencing Data of CCR5- and CXCR4-Using Variants. <i>PLoS ONE</i> , 2014, 9, e102857.	1.1	15

#	ARTICLE	IF	CITATIONS
19	Evaluation of Different Parameters of Humoral and Cellular Immune Responses in HIV Serodiscordant Heterosexual Couples: Humoral Response Potentially Implicated in Modulating Transmission Rates. <i>EBioMedicine</i> , 2017, 26, 25-37.	2.7	15
20	Host Genetic Factors Associated with Symptomatic Primary HIV Infection and Disease Progression among Argentinean Seroconverters. <i>PLoS ONE</i> , 2014, 9, e113146.	1.1	15
21	ICOS, SLAM and PD-1 expression and regulation on T lymphocytes reflect the immune dysregulation in patients with HIV-related illness with pulmonary tuberculosis. <i>Journal of the International AIDS Society</i> , 2012, 15, 17428.	1.2	12
22	Phenotype, Polyfunctionality, and Antiviral Activity of in vitro Stimulated CD8 <sup>+</sup> T-Cells From HIV+ Subjects Who Initiated cART at Different Time-Points After Acute Infection. <i>Frontiers in Immunology</i> , 2018, 9, 2443.	2.2	12
23	Low Rate of Emergence of Nevirapine and Lamivudine Resistance after Post-Partum Interruption of a Triple-Drug Regimen. <i>Antiviral Therapy</i> , 2008, 13, 135-140.	0.6	12
24	HIV+TB coinfection impairs CD8 <sup>+</sup> T cell differentiation and function while dehydroepiandrosterone improves cytotoxic antitubercular immune responses. <i>European Journal of Immunology</i> , 2015, 45, 2529-2541.	1.6	11
25	Liver cirrhosis in HIV/HCV coinfected individuals is related to NK cell dysfunction and exhaustion, but not to an impaired NK cell modulation by CD4 <sup>+</sup> T cells. <i>Journal of the International AIDS Society</i> , 2019, 22, e25375.	1.2	11
26	Hepatitis C Virus (HCV) Clearance After Treatment With Direct-Acting Antivirals in Human Immunodeficiency Virus (HIV)-HCV Coinfection Modulates Systemic Immune Activation and HIV Transcription on Antiretroviral Therapy. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa115.	0.4	11
27	Biomarkers of Progression after HIV Acute/Early Infection: Nothing Compares to CD4+ T-cell Count?. <i>Viruses</i> , 2018, 10, 34.	1.5	10
28	Longitudinal analysis of the 5'UTR, E2-PePHD and NS5A-PKRBD genomic regions of hepatitis C virus genotype 1a in association with the response to peginterferon and ribavirin therapy in HIV-coinfected patients. <i>Antiviral Research</i> , 2012, 95, 72-81.	1.9	8
29	Telomerase activity in peripheral blood mononuclear cells from HIV and HIV+HCV coinfected patients. <i>Virus Research</i> , 2010, 147, 284-287.	1.1	7
30	Previous failure of interferon-based therapy does not alter the frequency of HCV NS3 protease or NS5B polymerase inhibitor resistance-associated variants: longitudinal analysis in HCV/HIV co-infected patients. <i>International Journal of Antimicrobial Agents</i> , 2015, 46, 219-224.	1.1	7
31	Dynamics of SARS-CoV-2-specific antibodies among COVID19 biobank donors in Argentina. <i>Heliyon</i> , 2021, 7, e08140.	1.4	7
32	A clustering phenomenon among HCV1a strains among patients coinfecting with HIV from Buenos Aires, Argentina. <i>Journal of Medical Virology</i> , 2012, 84, 570-581.	2.5	6
33	Inter and intra-host variability of hepatitis C virus genotype 1a hypervariable envelope coding domains followed for a 11 year of human immunodeficiency virus coinfection and highly active antiretroviral therapy. <i>Virology</i> , 2014, 471-473, 19-28.	1.1	6
34	Modification of the HIV-specific CD8 <sup>+</sup> T-cell response in an HIV elite controller after chikungunya virus infection. <i>Aids</i> , 2016, 30, 1905-1911.	1.0	6
35	The Hepatitis C Virus 5'UTR Genomic Region Remains Highly Conserved Under HAART: A 4- to 8-Year Longitudinal Study from HCV/HIV Co-Infected Patients. <i>AIDS Research and Human Retroviruses</i> , 2010, 26, 527-532.	0.5	5
36	7-oxo-DHEA enhances impaired M. tuberculosis-specific T cell responses during HIV-TB coinfection. <i>Journal of Biomedical Science</i> , 2020, 27, 20.	2.6	4

#	ARTICLE	IF	CITATIONS
37	SARS-CoV-2 humoral and cellular immune responses in COVID-19 convalescent individuals with HIV. <i>Journal of Infection</i> , 2022, 85, 334-363.	1.7	4
38	Phylogenetic Diversity in Core Region of Hepatitis C Virus Genotype 1a as a Factor Associated with Fibrosis Severity in HIV-1-Coinfected Patients. <i>BioMed Research International</i> , 2017, 2017, 1-12.	0.9	3
39	CD4 <sup>+</sup> T cells and natural killer cells: Biomarkers for hepatic fibrosis in human immunodeficiency virus/hepatitis C virus-coinfected patients. <i>World Journal of Hepatology</i> , 2017, 9, 1073.	0.8	3
40	The Coughing Patient: TB or Not TB; That Is The Question. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2010, 54, 562-563.	0.9	2
41	Faldaprevir (BI 201335) for the treatment of hepatitis C in patients co-infected with HIV. <i>Expert Review of Anti-Infective Therapy</i> , 2014, 12, 157-164.	2.0	2
42	Pre-cART Immune Parameters in People Living With HIV Might Help Predict CD8 <sup>+</sup> T-Cell Characteristics, Inflammation Levels, and Reservoir Composition After Effective cART. <i>Pathogens and Immunity</i> , 2021, 6, 60-89.	1.4	2
43	Uncommon Hepatitis B Virus and/or Hepatitis C Virus Occult Infection in HIV-Positive Patients With Abnormal Level of Hepatic Enzyme. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2008, 49, 233-234.	0.9	1
44	HIV-1 Env-specific IgA/IgG Ratio Is Related to Antibody Dependent Cellular Cytotoxicity (ADCC) Responses Observed during Acute/Early HIV Infection. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A89-A89.	0.5	1
45	Evolution of hepatitis C virus in HIV coinfecting patients under antiretroviral therapy. <i>Infection, Genetics and Evolution</i> , 2016, 43, 186-196.	1.0	1
46	Immune variations throughout the course of tuberculosis treatment and its relationship with adrenal hormone changes in HIV-1 patients co-infected with <i>Mycobacterium tuberculosis</i> . <i>Tuberculosis</i> , 2021, 127, 102045.	0.8	0